Literature DB >> 18056275

Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum.

Diana Barthel1, Martin Schlitzer, Gabriele Pradel.   

Abstract

Antibacterial agents are used in malaria therapy due to their effect on two prokaryote organelles, the mitochondrion and the apicoplast. We demonstrate here that the ribosome-blocking antibiotics telithromycin and quinupristin-dalfopristin, but not linezolid, inhibit the growth of Plasmodium falciparum. Both drugs induce delayed death in the parasite, suggesting that their effect involves the impairment of apicoplast translation processes.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18056275      PMCID： PMC2224768          DOI： 10.1128/AAC.00892-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  35 in total

1.  In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.

Authors:  Amar Bir Singh Sidhu; Qingan Sun; Louis J Nkrumah; Michael W Dunne; James C Sacchettini; David A Fidock
Journal:  J Biol Chem       Date:  2006-11-15       Impact factor: 5.157

2.  Tetracyclines specifically target the apicoplast of the malaria parasite Plasmodium falciparum.

Authors:  Erica L Dahl; Jennifer L Shock; Bhaskar R Shenai; Jiri Gut; Joseph L DeRisi; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 3.  Why are plastid genomes retained in non-photosynthetic organisms?

Authors:  Adrian C Barbrook; Christopher J Howe; Saul Purton
Journal:  Trends Plant Sci       Date:  2006-01-09       Impact factor: 18.313

4.  Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum.

Authors:  T N C Ramya; Satyendra Mishra; Krishanpal Karmodiya; Namita Surolia; Avadhesha Surolia
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

5.  Studies in human malaria. XXIX. Trials of aureomycin, chloramphenicol, penicillin, and dihydrostreptomycin against the Chesson strain of Plasmodium vivax.

Authors:  C A IMBODEN; W C COOPER; G R COATNEY; G M JEFFERY
Journal:  J Natl Malar Soc       Date:  1950-12

Review 6.  Metabolic maps and functions of the Plasmodium mitochondrion.

Authors:  Giel G van Dooren; Luciana M Stimmler; Geoffrey I McFadden
Journal:  FEMS Microbiol Rev       Date:  2006-07       Impact factor: 16.408

7.  Development of the endoplasmic reticulum, mitochondrion and apicoplast during the asexual life cycle of Plasmodium falciparum.

Authors:  Giel G van Dooren; Matthias Marti; Christopher J Tonkin; Luciana M Stimmler; Alan F Cowman; Geoffrey I McFadden
Journal:  Mol Microbiol       Date:  2005-07       Impact factor: 3.501

Review 8.  Isoprenoid biosynthesis of the apicoplast as drug target.

Authors:  Jochen Wiesner; Hassan Jomaa
Journal:  Curr Drug Targets       Date:  2007-01       Impact factor: 3.465

Review 9.  Fatty acid biosynthesis as a drug target in apicomplexan parasites.

Authors:  C D Goodman; G I McFadden
Journal:  Curr Drug Targets       Date:  2007-01       Impact factor: 3.465

Review 10.  The plastid of Plasmodium spp.: a target for inhibitors.

Authors:  S Sato; R J M Wilson
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291
View more
  12 in total

1.  Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches.

Authors:  Eric H Ekland; Jessica Schneider; David A Fidock
Journal:  FASEB J       Date:  2011-07-11       Impact factor: 5.191

2.  Apicoplast-targeting antibacterials inhibit the growth of Babesia parasites.

Authors:  Mahmoud Aboulaila; Tserendorj Munkhjargal; Thillaiampalam Sivakumar; Akio Ueno; Yuki Nakano; Miki Yokoyama; Takeshi Yoshinari; Daisuke Nagano; Koji Katayama; Nasr El-Bahy; Naoaki Yokoyama; Ikuo Igarashi
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast.

Authors:  Makoah N Aminake; Sebastian Schoof; Ludmilla Sologub; Monika Leubner; Marc Kirschner; Hans-Dieter Arndt; Gabriele Pradel
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

4.  Ketolide agents HMR 3004 and HMR 3647 (telithromycin) inhibit the growth of Plasmodium falciparum in vitro.

Authors:  Marema Makgatho; Eric Maimela; Felix Mbajiorgu
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

5.  Insights into the preclinical treatment of blood-stage malaria by the antibiotic borrelidin.

Authors:  I G Azcárate; P Marín-García; N Camacho; S Pérez-Benavente; A Puyet; A Diez; L Ribas de Pouplana; J M Bautista
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

6.  In vitro and in vivo anti-malarial activity of tigecycline, a glycylcycline antibiotic, in combination with chloroquine.

Authors:  Rajnish Sahu; Larry A Walker; Babu L Tekwani
Journal:  Malar J       Date:  2014-10-21       Impact factor: 2.979

7.  Inhibition of the SR protein-phosphorylating CLK kinases of Plasmodium falciparum impairs blood stage replication and malaria transmission.

Authors:  Selina Kern; Shruti Agarwal; Kilian Huber; André P Gehring; Benjamin Strödke; Christine C Wirth; Thomas Brügl; Liliane Onambele Abodo; Thomas Dandekar; Christian Doerig; Rainer Fischer; Andrew B Tobin; Mahmood M Alam; Franz Bracher; Gabriele Pradel
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

Review 8.  Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria?

Authors:  Tiphaine Gaillard; Marylin Madamet; Francis Foguim Tsombeng; Jérôme Dormoi; Bruno Pradines
Journal:  Malar J       Date:  2016-11-15       Impact factor: 2.979

9.  Exploring anti-malarial potential of FDA approved drugs: an in silico approach.

Authors:  Gayatri Ramakrishnan; Nagasuma Chandra; Narayanaswamy Srinivasan
Journal:  Malar J       Date:  2017-07-18       Impact factor: 2.979

10.  Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads.

Authors:  Jagrati Jain; Surendra K Jain; Larry A Walker; Babu L Tekwani
Journal:  BMC Pharmacol Toxicol       Date:  2017-06-02       Impact factor: 2.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.